InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), announces that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index.
Marijuana Investing
Maricann Revises Convertible Debenture Terms
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF) announces that it has amended the terms of its previously announced private placement of convertible debenture units.
Canopy Growth Expands European Footprint with Spectrum Denmark
Canopy Growth Corporation (TSX: WEED) announces that it has established a binding strategic partnership in the emerging Danish market as part of its systematic expansion plan in Europe.
Algae Dynamics Corp. (ADYNF) Collaborates with University of Western Ontario
Algae Dynamics Corp. (OTCQB: ADYNF) is in a collaboration agreement with the University of Western Ontario (now rebranded as Western University), which is making international news with its recent study in Nature Scientific Reports.
InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media
CFN Media Group announces the publication of an article covering how InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) is leveraging biosynthesis to solve a major problem in the medical cannabis industry as it adds key ex-Eli Lilly personnel to its efforts.
Aurora Begins Supplying German Medical Cannabis Market
Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF) announced today that it has received all the required permits to ship dried cannabis flower from Canada to Germany.
Emerald Health Therapeutics Expands its Cannabis Supply with Purchase from Supreme Pharmaceuticals
Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF) today announced that its wholly owned subsidiary, Emerald Health Botanicals Inc., has completed a purchase of dried cannabis from Supreme Pharmaceuticals Inc.’s (TSXV:FIRE) subsidiary, 7ACRES.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Retains Consulting Services of Ben Paterson
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for scale-up, purification and manufacturing strategies related to the company’s cannabinoid biosynthesis program.
InMed (CSE: IN; OTCQB: IMLFF) Retains Consultant Ben Paterson for Biosynthesis Development
InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) announced today that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for the scale-up, purification, and manufacturing strategies for InMed’s cannabinoid biosynthesis program.
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Nets Total Proceeds of $11.9 Million from Exercise of Warrants
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has received total proceeds of nearly $11.9 million from the exercise of an aggregate of 19,185,965 warrants since the closing of its acquisition of ABcann Medicinals Inc. on April 28, 2017.
The Green Organic Dutchman Holdings Ltd. Announces Financing Syndicate for $20 Million Offering
he Green Organic Dutchman Holdings Ltd. announces the syndicate for the offering of 4,242,500 Units of the Company at a price of C$1.65 per Unit for aggregate gross proceeds of C$7,000,125.
ABcann Global Receives $11.9 Million from Exercise of Warrants
ABcann Global receives $11.9 Million from the exercise of outstanding warrants.
The Bio Pharma Project Generator
StockHouse did an in-depth look at InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) about their model, technology and the "Big Picture"
ChineseInvestors.com, Inc. (CIIX) Subsidiary Completes China FDA Filing; Moves toward Launch of Hemp-Infused Skin Care Line
Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX), through wholly-owned subsidiary CBD Biotechnology Co. Ltd., this morning announced that it has completed the record filing process with the China Food & Drug Administration (“CFDA”) for its first line of non-industrial hemp-infused skin care products.
Copy of ABcann Global Receives $11.9 Million from Exercise of Warrants
ABcann Global receives $11.9 Million from the exercise of outstanding warrants.